Nephros (NEPH) AI Stock Analysis

• Market Cap: $36.47M
• Dividend Yield: N/A
• Average Volume (3M): 49.04K
• Price to Earnings (P/E): 45.6
• Beta (1Y): -0.37
• Revenue Growth: 10.34%
• EPS Growth: N/A
• Country: US
• Employees: 31
• Sector: Healthcare
• Sector Strength: 37
• Industry: Medical - Instruments & Supplies
• EPS (TTM): 0.05
• Shares Outstanding: 10,600,350
• 10 Day Avg. Volume: 18,188
• 30 Day Avg. Volume: 49,043
• PEG Ratio: 0.05
• Price to Book (P/B): 4.16
• Price to Sales (P/S): 0.00
• P/FCF Ratio: 86.44
• Enterprise Value/Market Cap: 0.98
• Enterprise Value/Revenue: 0.63
• Enterprise Value/Gross Profit: 3.70
• Enterprise Value/Ebitda: -57.32
• 1Y Price Target: $4.50
• Price Target Upside: 30.81% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 1

• Rating: 61 Neutral
• Price Target: $4.00 ▲(16.28%Upside)

Nephros is demonstrating positive trends in financial performance and technical analysis, with improving profitability and bullish stock momentum. However, the high P/E ratio indicates a potential overvaluation, suggesting caution. The company's financial stability is a strong positive, but challenges in revenue growth and cash flow management remain.

Positive Factors

Customer Expansion

NEPH added roughly 100 new Active Customer Sites, increasing its customer base to approximately 1,600, demonstrating growth in customer reach.

Financial Performance

NEPH reported revenue, gross margin, and GAAP EPS above both consensus and analyst estimates, indicating strong financial performance.

Product Innovation

The launch of the S100 In-Line microfilter provides enhanced installation flexibility, promoting broader use in low-pressure plumbing applications.

Negative Factors

Cash Position

Despite having no debt, NEPH's cash and equivalents stand at $4.1M, which could be a concern for liquidity management.

Market Valuation

Nephros trades at a lower EV/revenue multiple compared to peers, suggesting the market may undervalue its potential growth.

Nephros Business Overview & Revenue Model

Company Description

Nephros, Inc. develops and sells high performance water solutions to the medical and commercial markets in the United States. The company operates in three segments: Water Filtration, Pathogen Detection, and Renal Products. It offers ultrafiltration products that are used in dialysis centers for the removal of biological contaminants from water and bicarbonate concentrate; and in hospitals for the prevention of infection from waterborne pathogens, such as legionella and pseudomonas, as well as in military and outdoor recreation, commercial, and other healthcare facilities. The company also develops and sells real-time water testing systems to provide actionable data on waterborne pathogens; and medical device products for patients with renal disease, including a 2nd generation hemodiafiltration system for the treatment of patients with end stage renal disease. In addition, it offers water filters that improve the taste and odor of water, as well as reduce biofilm, bacteria, and scale build-up in downstream equipment under the Nephros and AETHER brands for the food service, hospitality, convenience store, and health care markets. The company was incorporated in 1997 and is headquartered in South Orange, New Jersey.

How the Company Makes Money

Nephros generates revenue through the sale of its water filtration and purification products. The company's primary revenue streams include direct sales to healthcare facilities, dialysis centers, and commercial entities. Nephros also engages in partnerships and distribution agreements to expand its market reach and enhance product availability. Revenue is further supported by repeat sales of consumable filter cartridges, which require regular replacement to maintain optimal filtration performance. The company's focus on innovation and quality positions it to effectively serve industries where water purity is critical.

Nephros Financial Statement Overview

Summary

Nephros is on a path to profitability with improving net income and gross margins. The company's low leverage and strong equity position provide financial stability. However, challenges remain in generating consistent revenue growth and positive cash flow, necessitating a focus on operational efficiency and cash management.

Income Statement

Nephros has shown improvements in net income, transitioning from a loss in previous years to a profit in the most recent year. The gross profit margin increased from 57% to 62%, indicating improved cost efficiency. However, revenue has slightly decreased over the past year, and EBIT and EBITDA margins remain thin, suggesting challenges in operational efficiency.

Balance Sheet

The balance sheet reflects a stable equity position with a debt-to-equity ratio of 0.16, indicating low leverage. The equity ratio remains strong at 76.6%, reflecting a solid capital structure. Despite declining total assets, the company's liabilities have decreased, enhancing financial stability.

Cash Flow

Cash flow from operations turned negative this year, reversing from a positive position last year. Free cash flow growth was negative, indicating a need for better cash management. The operating cash flow to net income ratio is unfavorable, suggesting room for improvement in cash generation relative to profitability.

Breakdown	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	14.16M	14.24M	9.97M	10.22M	8.56M
Gross Profit	8.72M	8.40M	4.73M	5.63M	4.91M
EBITDA	227.00K	-1.36M	-3.69M	-2.49M	-4.21M
Net Income	74.00K	-1.57M	-4.55M	-4.11M	-4.77M
Balance Sheet
Total Assets	11.21M	11.86M	11.00M	17.65M	18.51M
Cash, Cash Equivalents and Short-Term Investments	3.76M	4.31M	3.63M	6.97M	8.25M
Total Debt	1.41M	1.84M	1.09M	1.12M	2.17M
Total Liabilities	2.63M	3.50M	2.12M	2.90M	2.94M
Stockholders Equity	8.59M	8.36M	5.59M	11.70M	12.52M
Cash Flow
Free Cash Flow	-547.00K	752.00K	-3.37M	-1.45M	-7.14M
Operating Cash Flow	-492.00K	827.00K	-3.23M	-1.42M	-6.90M
Investing Cash Flow	-50.00K	-75.00K	-137.00K	-85.00K	-239.00K
Financing Cash Flow	-5.00K	-79.00K	34.00K	237.00K	11.22M

Nephros Technical Analysis

• Technical Analysis Sentiment: Neutral
• Last Price: 3.44
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For NEPH, the sentiment is Neutral. The current price of 3.44 is below the 20-day moving average (MA) of 3.80, above the 50-day MA of 3.40, and above the 200-day MA of 2.06, indicating a neutral trend. The MACD of >-0.01 indicates Positive momentum. The RSI at 47.10 is Neutral, neither overbought nor oversold. The STOCH value of 20.29 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for NEPH.

Nephros Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
NEPH	61 Neutral	$36.47M	45.56	9.17%	―	10.34%	―
POCI	56 Neutral	$37.56M	―	-47.37%	―	-9.20%	-232.02%
HBIO	53 Neutral	$25.20M	―	-138.80%	―	-14.41%	-549.88%
RVP	52 Neutral	$21.11M	―	-25.89%	―	-16.05%	-195.28%
Sector *	50 Neutral	AU$2.62B	3.32	-57.47%	2.40%	36.73%	13.67%
FEMY	40 Neutral	$29.77M	―	-239.87%	―	61.97%	-6.89%
MLSS	40 Underperform	$46.69M	―	-88.36%	―	-9.13%	30.04%

Nephros Corporate Events

Nephros Holds Annual Stockholders Meeting June 2025

On June 16, 2025, Nephros, Inc. conducted its Annual Meeting of Stockholders where several key decisions were made. Stockholders elected Lisa Nettis to the Board of Directors for a term ending in 2028, ratified Baker Tilly US, LLP as the independent public accounting firm for 2025, and approved the executive officers’ compensation on a non-binding basis. These decisions reflect the company’s ongoing governance and operational strategies.

The most recent analyst rating on (NEPH) stock is a Buy with a $4.50 price target. To see the full list of analyst forecasts on Nephros stock, see the NEPH Stock Forecast page.

Nephros Board Member Alisa Lask to Step Down

On April 23, 2025, Alisa Lask informed Nephros, Inc. that she will not seek re-election to the Board of Directors at the upcoming annual stockholders meeting on June 16, 2025. Her decision is not due to any disagreements with the company’s operations or policies.